These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 23946212

  • 21. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 22. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M, Azarkeivan A, Zareifar S, Cohan N, Bordbar MR, Haghpanah S.
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [Abstract] [Full Text] [Related]

  • 23. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C, Roccabruna E, D'Ascola DG.
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [Abstract] [Full Text] [Related]

  • 24. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E, Kaya B, Gadong N, Hemmaway C, Newell H, Simmons A, Whitmarsh S, Telfer P.
    Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
    [Abstract] [Full Text] [Related]

  • 25. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 26. Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
    Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E.
    Blood Cells Mol Dis; 2013 Feb 15; 50(2):99-104. PubMed ID: 23151373
    [Abstract] [Full Text] [Related]

  • 27. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A, Khoriaty E, Musallam KM, Taher AT.
    Am J Hematol; 2010 Oct 15; 85(10):782-6. PubMed ID: 20721892
    [No Abstract] [Full Text] [Related]

  • 28. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.
    Acta Haematol; 2008 Oct 15; 119(3):133-41. PubMed ID: 18408362
    [Abstract] [Full Text] [Related]

  • 29. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Oct 15; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 30. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
    Cancado R, Olivato MC, Bruniera P, Szarf G, de Moraes Bastos R, Rezende Melo M, Chiattone C.
    Acta Haematol; 2012 Oct 15; 128(2):113-8. PubMed ID: 22760067
    [Abstract] [Full Text] [Related]

  • 31. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH, Shu KH, Yang Y.
    Hematology; 2015 Jun 15; 20(5):304-10. PubMed ID: 25200910
    [Abstract] [Full Text] [Related]

  • 32. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May 15; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 33. Iron-chelating therapy for transfusional iron overload.
    Brittenham GM.
    N Engl J Med; 2011 Jan 13; 364(2):146-56. PubMed ID: 21226580
    [Abstract] [Full Text] [Related]

  • 34. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Jan 13; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 13; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 36. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
    Kennedy GA, Morris KL, Subramonpillai E, Curley C, Butler J, Durrant S.
    Br J Haematol; 2013 Jun 13; 161(6):794-801. PubMed ID: 23590671
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB.
    Br J Haematol; 2009 Dec 13; 147(5):752-9. PubMed ID: 19764988
    [Abstract] [Full Text] [Related]

  • 38. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, Romero-Jimenez RM, Sanjurjo-Saez M.
    J Clin Pharm Ther; 2016 Feb 13; 41(1):59-63. PubMed ID: 26778738
    [Abstract] [Full Text] [Related]

  • 39. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 40. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU.
    Pediatr Blood Cancer; 2009 May 21; 52(5):616-20. PubMed ID: 19148949
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.